Mechanisms of drug toxicity and relevance to pharmaceutical development

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 1, 2011, Pages 3-14

  Peter Guengerich, F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Covalent binding; Drugs; Idiosyncratic responses; Mechanisms; Short term assays; Toxicity

Indexed keywords

ALPIDEM; AMINEPTINE; BENDAZAC; BENZARONE; BENZIODARONE; BIOLOGICAL MARKER; BROMFENAC; CHLORMEZANONE; CINCHOPHEN; CLOMETACIN; CYCLOFENIL; DILEVALOL; EBROTIDINE; EXIFONE; FENCLOZIC ACID; FIPEXIDE; GLAFENINE; HALOTHANE; IBUFENAC; ISAXONINE; ISONIAZID; NIALAMIDE; NOMIFENSINE; OXYPHENISATINE; PARACETAMOL; PERHEXILINE; TIENILIC ACID; UNINDEXED DRUG; XENAZOIC ACID; ZIMELDINE;

CLINICAL TRIAL (TOPIC); DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG TOXICITY; HUMAN; HYPOTHESIS; LIVER TOXICITY; NONHUMAN; POSTMARKETING SURVEILLANCE; REVIEW;

EID: 79952771693     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RV-062     Document Type: Review

References (81)

1. U.S. Food and Drug Administration: Challenge and opportunity on the critical path to new medical products. US Department of Health and Human Services, March 2004.
2. Kola, I. and Landis, J.: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 3: 711-715 2004.
3. Borzelleca, J. F.: Paracelsus: herald of modern toxicology. Toxicol. Sci., 53: 2-4 2000.
4. Liebler, D. C. and Guengerich, F. P.: Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov., 4: 410-420 2005.
5. Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M. and Williams, D. P.: The role of metabolic activation in druginduced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol., 45: 177-202 2005.
6. Johnson, T. E., Zhang, X., Bleicher, K. B., Dysart, G., Loughlin, A. F., Schaefer, W. H. and Umbenhauer, D. R.: Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol. Appl. Pharmacol., 200: 237-250 2004.
7. Zipes, D. P., Zvaifler, N. J., Glassock, R. J., Gilman, S., Munoz, A., Gogolak, V., Gordis, L., Dedon, P. C., Guengerich, F. P., Wasserman, S. I., Witztum, J. L. and Wogan, G. N.: Rosuvastatin: an independent analysis of risks and benefits. MedGenMed, 8: 73 2006.
8. Landsteiner, K. and Jacobs, J.: Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med., 61: 643-656 1935.
9. nd ed. Philadelphia, Lippincott, Williams & Wilkins, 1999.
10. Bjornsson, E.: Drug-induced liver injury: Hyös rule revisited. Clin. Pharmacol. Ther., 79: 521-528 2006.
11. Uetrecht, J.: Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol., 47: 513-539 2007.
12. Uetrecht, J.: Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol., 21: 84-92 2008.
13. Uetrecht, J.: Immune-mediated adverse drug reactions. Chem. Res. Toxicol., 22: 24-34 2009.
14. Adams, D. H., Ju, C., Ramaiah, S. K., Uetrecht, J. and Jaeschke, H.: Mechanisms of immune-mediated liver injury. Toxicol. Sci., 115: 307-321 2010.
15. Uetrecht, J. P.: New concepts in immunology relevant to idiosyncratic drug reactions: the údanger hypothesisû and innate immune system. Chem. Res. Toxicol., 12: 387-395 1999.
16. Shenton, J. M., Chen, J. and Uetrecht, J. P.: Animal models of idiosyncratic drug reactions. Chem. Biol. Interact., 150: 53-70 2004.
17. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjoqvist, F. and Ingelman-Sundberg, M.: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A., 90: 11825-11829 1993.
18. Beaune, P., Pessayre, D., Dansette, P., Mansuy, D. and Manns, M.: Autoantibodies against cytochromes P450: role in human diseases. Adv. Pharmacol., 30: 199-245 1994.
19. Bourdi, M., Larrey, D., Nataf, J., Berunau, J., Pessayre, D., Iwasaki, M., Guengerich, F. P. and Beaune, P. H.: A new anti-liver endoplasmic reticulum antibody directed against human cytochrome P-450 IA2: a specific marker of dihydralazine-induced hepatitis. J. Clin. Invest., 85: 1967-1973 1990.
20. Dansette, P. M., Bonierbale, E., Minoletti, C., Beaune, P. H., Pessayre, D. and Mansuy, D.: Drug-induced immunotoxicity. Eur. J. Drug Metab. Pharmacokinet., 23: 443-451 1998.
21. Ganey, P. E., Luyendyk, J. P., Maddox, J. F. and Roth, R. A.: Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem. Biol. Interact., 150: 35-51 2004.
22. Luyendyk, J. P., Shores, K. C., Ganey, P. E. and Roth, R. A.: Bacterial lipopolysaccharide exposure alters aflatoxin B1 hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci., 68: 220-225 2002.
23. Matzinger, P.: The danger model: a renewed sense of self. Science, 296: 301-305 2002.
24. Matzinger, P.: Friendly and dangerous signals: is the tissue in control? Nat. Immunol., 8: 11-13 2007.
25. Pichler, W. J.: Delayed drug hypersensitivity reactions. Ann. Intern. Med., 139: 683-693 2003.
26. Gerber, B. O. and Pichler, W. J.: Cellular mechanisms of T cell mediated drug hypersensitivity. Curr. Opin. Immunol., 16: 732-737 2004.
27. Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., Carlsson, S., Cederbrant, K. E., Gibson, N. J., Armstrong, M., Lagerström-Fermér, M. E., Dellsén, A., Brown, E. M., Thornton, M., Dukes, C., Jenkins, S. C., Firth, M. A., Harrod, G. O., Pinel, T. H., Billing-Clason, S. M. E., Cardon, L. R. and March, R. E.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenet. J., 8: 186-195 2008.
28. Guengerich, F. P. and MacDonald, J. S.: Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol., 20: 344-369 2007.
29. Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R. and Brodie, B. B.: Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther., 187: 195-202 1973.
30. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R. and Brodie, B. B.: Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther., 187: 185-194 1973.
31. Miller, E. C. and Miller, J. A.: The presence and significance of bound amino azodyes in the livers of rats fed p-dimethylaminoazobenzene. Cancer Res., 7: 468-480 1947.
32. Bakke, O. M., Wardell, W. M. and Lasagna, L.: Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin. Pharmacol. Ther., 35: 559-567 1984.
33. Bakke, O. M., Manocchia, M., de Abajo, F., Kaitin, K. I. and Lasagna, L.: Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin. Pharmacol. Ther., 58: 108-117 1995.
34. Wysowski, D. K. and Swartz, L.: Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch. Intern. Med., 165: 1363-1369 2005.
35. Walgren, J. L., Mitchell, M. D. and Thompson, D. C.: Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol., 35: 325-361 2005.
36. Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R. and Corcoran, G. B., 3rd: Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science, 193: 901-903 1976.
37. Bradbury, A., Powell, G. M., Curtis, C. G. and Rhodes, C.: The enhanced biliary secretion of a taurine conjugate in the rat after intraduodenal administration of high doses of fenclozic acid. Xenobiotica, 11: 665-674 1981.
38. Mathison, B. H., Murphy, S. E. and Shank, R. C.: Hydralazine and other hydrazine derivatives and the formation of DNA adducts. Toxicol. Appl. Pharmacol., 127: 91-98 1994.
39. Qiu, Y., Burlingame, A. L. and Benet, L. Z.: Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. Drug Metab. Dispos., 26: 246-256 1998.
40. Obach, R. S. and Dalvie, D. K.: Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase-A, and cytochrome P450 enzymes. Drug Metab. Dispos., 34: 1310-1316 2006.
41. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G. and Baillie, T. A.: Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol., 14: 62-70 2001.
42. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., OöDonnell, J. P., Boer, J. and Harriman, S. P.: A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 6: 161-225 2005.
43. Durand, A., Thenot, J. P., Bianchetti, G. and Morselli, P. L.: Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev., 24: 239-266 1992.
44. Geneve, J., Larrey, D., Letteron, P., Descatoire, V., Tinel, M., Amouyal, G. and Pessayre, D.: Metabolic activation of the tricyclic antidepressant amineptine. I. Cytochrome P-450-mediated in vitro covalent binding. Biochem. Pharmacol., 36: 323-329 1987.
45. Castillo, M. and Smith, P. C.: Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab. Dispos., 23: 566-572 1995.
46. Martinat, C., Amar, C., Dansette, P. M., Leclaire, J., Lopez-Garcia, P., Cao, T. D., NöGuyen, H. N. and Mansuy, D.: In vitro metabolism of isaxonine phosphate: formation of two metabolites, 5-hydroxyisaxonine and 2-aminopyrimidine, and covalent binding to microsomal proteins. Eur. J. Pharmacol., 228: 63-71 1992.
47. Reid, J. M., Kuffel, M. J., Miller, J. K., Rios, R. and Ames, M. M.: Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin. Cancer Res., 5: 2192-2197 1999.
48. Arnold, T. H., Jr., Epps, J. M., 3rd, Cook, H. R. and Hamrick, M. E.: Dantrolene sodium: urinary metabolites and hepatotoxicity. Res. Commun. Chem. Pathol. Pharmacol., 39: 381-398 1983.
49. Dieckhaus, C. M., Santos, W. L., Sofia, R. D. and Macdonald, T. L.: The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: a reactive metabolite in felbamate bioactivation. Chem. Res. Toxicol., 14: 958-964 2001.
50. Berson, A., Wolf, C., Chachaty, C., Fisch, C., Fau, D., Eugene, D., Loeper, J., Gauthier, J. C., Beaune, P., Pompon, D., Maurel, P. and Pessayre, D.: Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochrome P-450, including forms belonging to the 3A and 1A subfamilies. J. Pharmacol. Exp. Ther., 265: 366-372 1993.
51. Cohen, A. D., Luger, S. M., Sickles, C., Mangan, P. A., Porter, D. L., Schuster, S. J., Tsai, D. E., Nasta, S., Gewirtz, A. M. and Stadtmauer, E. A.: Gemtuzumab ozogamicin Mylotarg monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant., 30: 23-28 2002.
52. Timbrell, J. A., Mitchell, J. R., Snodgrass, W. R. and Nelson, S. D.: Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J. Pharmacol. Exp. Ther., 213: 364-369 1980.
53. Rodriguez, R. J. and Acosta, D., Jr.: N-Deacetyl ketoconazoleinduced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology, 117: 123-131 1997.
54. Smith, K. S., Smith, P. L., Heady, T. N., Trugman, J. M., Harman, W. D. and Macdonald, T. L.: In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol., 16: 123-128 2003.
55. Baillie, T. A.: Metabolic activation of valproic acid and drugmediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4- pentenoic acid. Chem. Res. Toxicol., 1: 195-199 1988.
56. Uetrecht, J. P.: Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr. Drug Metab., 1: 133-141 2000.
57. Masubuchi, N., Makino, C. and Murayama, N.: Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol., 20: 455-464 2007.
58. Obach, R. S., Kalgutkar, A. S., Soglia, J. R. and Zhao, S. X.: Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol., 21: 1814-1822 2008.
59. Bauman, J. N., Kelly, J. M., Tripathy, S., Zhao, S. X., Lam, W. W., Kalgutkar, A. S. and Obach, R. S.: Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol., 22: 332-340 2009.
60. Gan, J., Ruan, Q., He, B., Zhu, M., Shyu, W. C. and Humphreys, W. G.: In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation. Chem. Res. Toxicol., 22: 690-698 2009.
61. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A. and Baillie, T. A.: Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 17: 3-16 2004.
62. Streeter, A. J., Bjorge, S. M., Axworthy, D. B., Nelson, S. D. and Baillie, T. A.: The microsomal metabolism and site of covalent binding to protein of 3$-hydroxyacetanilide, a non-hepatotoxic positional isomer of acetaminophen. Drug Metab. Dispos., 12: 565-576 1984.
63. Roberts, S. A., Price, V. F. and Jollow, D. J.: Acetaminophen structure-toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide. Toxicol. Appl. Pharmacol., 105: 195-208 1990.
64. Tirmenstein, M. A. and Nelson, S. D.: Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a non-hepatotoxic regioisomer, 3$-hydroxyacetanilide, in mouse liver. J. Biol. Chem., 264: 9814-9819 1989.
65. Jones, D. P., Lemasters, J. J., Han, D., Boelsterli, U. A. and Kaplowitz, N.: Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol. Interv., 10: 98-111 2010.
66. Bansal, S., Liu, C.-P., Sepuri, N. B. V., Anandatheerthavarada, H. K., Milne, G. L., Guengerich, F. P. and Avadhani, N. G.: Mitochondria-targeted cytochrome P450 2E1 preferentially induces oxidative damage and augments alcohol mediated mitochondrial dysfunction in cultured cells. J. Biol. Chem., 285: 24609-24619 2010.
67. Boelsterli, U. A. and Lim, P. L.: Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol., 220: 92-107 2007.
68. Lee, Y. H., Chung, M. C. M., Sin, Q. and Boelsterli, U. A.: Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2+/% mice: Two-stage oxidative injury. Toxicol. Appl. Pharmacol., 231: 43-51 2008.
69. Ryan, T. P., Stevens, J. L. and Thomas, C. E.: Strategic applications of toxicogenomics in early drug discovery. Curr. Opin. Pharmacol., 8: 654-660 2008.
70. Davis, J. W. and Kramer, J. A.: Genomic-based biomarkers of drug-induced nephrotoxicity. Expert Opin. Drug Metab. Toxicol., 2: 95-101 2006.
71. Ganter, B., Snyder, R. D., Halbert, D. N. and Lee, M. D.: Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix¬ database. Pharmacogenomics, 7: 1025-1044 2006.
72. Hu, W., Sorrentino, C., Denison, M. S., Kolaja, K. and Fielden, M. R.: Induction of Cyp1A1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol. Pharmacol., 71: 1475-1486 2007.
73. Amacher, D. E.: The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol. Appl. Pharmacol., 245: 134-142 2010.
74. Dieterle, F., Perentes, E., Cordier, A., Roth, D. R., Verdes, P., Grenet, O., Pantano, S., Moulin, P., Wahl, D., Mahl, A., End, P., Staedtler, F., Legay, F., Carl, K., Laurie, D., Chibout, S. D., Vonderscher, J. and Maurer, G.: Urinary clusterin, cystatin C, Ç2- microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotechnol., 28: 463-469 2010.
75. Yu, Y., Jin, H., Holder, D., Ozer, J. S., Villarreal, S., Shughrue, P., Shi, S., Figueroa, D. J., Clouse, H., Su, M., Muniappa, N., Troth, S. P., Bailey, W., Seng, J., Aslamkhan, A. G., Thudium, D., Sistare, F. D. and Gerhold, D. L.: Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat. Biotechnol., 28: 470-477 2010.
76. Vaidya, V. S., Ozer, J. S., Dieterle, F., Collings, F. B., Ramirez, V., Troth, S., Muniappa, N., Thudium, D., Gerhold, D., Holder, D. J., Bobadilla, N. A., Marrer, E., Perentes, E., Cordier, A., Vonderscher, J., Maurer, G., Goering, P. L., Sistare, F. D. and Bonventre, J. V.: Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol., 28: 478-485 2010.
77. Ozer, J. S., Dieterle, F., Troth, S., Perentes, E., Cordier, A., Verdes, P., Staedtler, F., Mahl, A., Grenet, O., Roth, D. R., Wahl, D., Legay, F., Holder, D., Erdos, Z., Vlasakova, K., Jin, H., Yu, Y., Muniappa, N., Forest, T., Clouse, H. K., Reynolds, S., Bailey, W. J., Thudium, D. T., Topper, M. J., Skopek, T. R., Sina, J. F., Glaab, W. E., Vonderscher, J., Maurer, G., Chibout, S. D., Sistare, F. D. and Gerhold, D. L.: A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotechnol., 28: 486-494 2010.
78. Sanderson, D. M. and Earnshaw, C. G.: Computer prediction of possible toxic action from chemical structure; the DEREK system. Hum. Exp. Toxicol., 10: 261-273 1991.
79. Greene, N., Judson, P. N., Langowski, J. J. and Marchant, C. A.: Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ. Res., 10: 299-314 1999.
80. Deardon, J. C.: In silico prediction of ADMET properties: how far have we come? Expert Opin. Drug Metab. Toxicol., 3: 635-639 2007.
81. Greene, N., Fisk, L., Naven, R. T., Note, R. R., Patel, M. L. and Pelletier, D. J.: Developing structure-activity relationships for the prediction of hepatotoxicity. Chem. Res. Toxicol., 23: 1215-1222 2010.